Santen Pharmaceutical Co., Ltd. (TSE:4536) announces a share repurchase program. Under the program, the company will repurchase up to 21,110,000 of its common shares, representing 5.81% of its outstanding shares for ¥38,000 million. The purpose of the program is to enhance capital efficiency and improve return of profits based on a comprehensive consideration of factors such as profitability improvement and business environment in accordance with the capital allocation policy in the medium-term management plan.

The repurchased shares will be cancelled. The plan will be valid up to November 6, 2024. As on March 31, 2024, the company had 363,258,785 shares outstanding and 737,469 shares in its treasury.